Table 3.
In vitro antibacterial resistance, MIC50, and MIC90 of clinical K. pneumoniae strains (n = 29).
| Antibiotics |
Breakpoint µg/mL |
MIC50 µg/mL |
MIC90 µg/mL |
Resistant strains n (%) |
|---|---|---|---|---|
| Amikacin | ≥ 64 | 32 | > 512 | 14 (48.3) |
| Co-amoxiclav | ≥ 32/16 | ≥ 128/64 | ≥ 128/64 | 24 (82.8) |
| Ampicillin-sulbactam | ≥ 32/16 | ≥ 256/128 | ≥ 256/128 | 28 (96.6) |
| Aztreonam | ≥ 16 | > 16 | > 16 | 24 (82.8) |
| Cefepime | ≥ 16 | > 128 | > 128 | 28 (96.6) |
| Cefotaxime | ≥ 4 | > 32 | > 32 | 29 (1 0 0) |
| Cefoxitin | ≥ 32 | > 128 | > 128 | 24 (82.8) |
| Ceftazidime | ≥ 16 | > 128 | > 128 | 26 (89.7) |
| Cefuroxime | ≥ 4 | > 256 | > 256 | 29 (1 0 0) |
| Ciprofloxacin | ≥ 1 | > 32 | > 32 | 25 (86.2) |
| Ertapenem | ≥ 2 | > 32 | > 32 | 26 (89.7) |
| Gentamicin | ≥ 16 | 64 | > 128 | 20 (69) |
| Imipenem | ≥ 4 | > 32 | > 32 | 24 (82.8) |
| Levofloxacin | ≥ 2 | > 64 | > 64 | 24 (82.8) |
| Meropenem | ≥ 4 | > 32 | > 32 | 24 (82.8) |
| Moxifloxacin | > 1 | > 64 | > 64 | 26 (89.7) |
| Piperacillin-tazobactam | ≥ 128/4 | > 128/4 | > 128/4 | 25 (86.2) |
| Tigecycline | ≥ 2 | 2 | > 32 | 9 (31) |
| Tobramycin | ≥ 16 | 32 | > 128 | 22 (75.9) |
| Co-trimoxazole | ≥ 4/76 | 16/304 | > 32/608 | 27 (93.1) |
| Colistin | ≥ 4 | 1 | 8 | 6 (20.7) |
MIC minimum inhibitory concentration.